These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 22751131)

  • 1. Oncogenic B-Raf signaling in melanoma cells controls a network of microRNAs with combinatorial functions.
    Couts KL; Anderson EM; Gross MM; Sullivan K; Ahn NG
    Oncogene; 2013 Apr; 32(15):1959-70. PubMed ID: 22751131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Critical role of miR-10b in B-RafV600E dependent anchorage independent growth and invasion of melanoma cells.
    Datar I; Kalpana G; Choi J; Basuroy T; Trumbly R; Chaitanya Arudra SK; McPhee MD; de la Serna I; Yeung KC
    PLoS One; 2019; 14(4):e0204387. PubMed ID: 30995246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-derived fibronectin is involved in melanoma cell invasion and regulated by V600E B-Raf signaling pathway.
    Gaggioli C; Robert G; Bertolotto C; Bailet O; Abbe P; Spadafora A; Bahadoran P; Ortonne JP; Baron V; Ballotti R; Tartare-Deckert S
    J Invest Dermatol; 2007 Feb; 127(2):400-10. PubMed ID: 16960555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncogenic BRAF(V600E) inhibits BIM expression to promote melanoma cell survival.
    Cartlidge RA; Thomas GR; Cagnol S; Jong KA; Molton SA; Finch AJ; McMahon M
    Pigment Cell Melanoma Res; 2008 Oct; 21(5):534-44. PubMed ID: 18715233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upregulation of MicroRNA-1246 Is Associated with BRAF Inhibitor Resistance in Melanoma Cells with Mutant BRAF.
    Kim JH; Ahn JH; Lee M
    Cancer Res Treat; 2017 Oct; 49(4):947-959. PubMed ID: 28052651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic targeting of B-RafV600E affects survival and proliferation and identifies selective agents against BRAF-mutant colorectal cancer cells.
    Hirschi B; Gallmeier E; Ziesch A; Marschall M; Kolligs FT
    Mol Cancer; 2014 May; 13():122. PubMed ID: 24885690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RAF-Mutant Melanomas Differentially Depend on ERK2 Over ERK1 to Support Aberrant MAPK Pathway Activation and Cell Proliferation.
    Crowe MS; Zavorotinskaya T; Voliva CF; Shirley MD; Wang Y; Ruddy DA; Rakiec DP; Engelman JA; Stuart DD; Freeman AK
    Mol Cancer Res; 2021 Jun; 19(6):1063-1075. PubMed ID: 33707308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human melanoma cells expressing V600E B-RAF are susceptible to IGF1R targeting by small interfering RNAs.
    Yeh AH; Bohula EA; Macaulay VM
    Oncogene; 2006 Oct; 25(50):6574-81. PubMed ID: 16715137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells.
    Stuart SA; Houel S; Lee T; Wang N; Old WM; Ahn NG
    Mol Cell Proteomics; 2015 Jun; 14(6):1599-615. PubMed ID: 25850435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.
    Hoeflich KP; Herter S; Tien J; Wong L; Berry L; Chan J; O'Brien C; Modrusan Z; Seshagiri S; Lackner M; Stern H; Choo E; Murray L; Friedman LS; Belvin M
    Cancer Res; 2009 Apr; 69(7):3042-51. PubMed ID: 19276360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.
    Penna I; Molla A; Grazia G; Cleris L; Nicolini G; Perrone F; Picciani B; Del Vecchio M; de Braud F; Mortarini R; Anichini A
    Oncotarget; 2016 Jan; 7(4):3947-65. PubMed ID: 26678033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of Brahma expression by the mitogen-activated protein kinase/extracellular signal regulated kinase pathway is associated with changes in melanoma proliferation.
    Mehrotra A; Saladi SV; Trivedi AR; Aras S; Qi H; Jayanthy A; Setaluri V; de la Serna IL
    Arch Biochem Biophys; 2014 Dec; 563():125-35. PubMed ID: 25026375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutation of B-Raf in human choroidal melanoma cells mediates cell proliferation and transformation through the MEK/ERK pathway.
    Calipel A; Lefevre G; Pouponnot C; Mouriaux F; Eychène A; Mascarelli F
    J Biol Chem; 2003 Oct; 278(43):42409-18. PubMed ID: 12917419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.
    Nazarian R; Shi H; Wang Q; Kong X; Koya RC; Lee H; Chen Z; Lee MK; Attar N; Sazegar H; Chodon T; Nelson SF; McArthur G; Sosman JA; Ribas A; Lo RS
    Nature; 2010 Dec; 468(7326):973-7. PubMed ID: 21107323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A mortalin/HSPA9-mediated switch in tumor-suppressive signaling of Raf/MEK/extracellular signal-regulated kinase.
    Wu PK; Hong SK; Veeranki S; Karkhanis M; Starenki D; Plaza JA; Park JI
    Mol Cell Biol; 2013 Oct; 33(20):4051-67. PubMed ID: 23959801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FOXD3 is a mutant B-RAF-regulated inhibitor of G(1)-S progression in melanoma cells.
    Abel EV; Aplin AE
    Cancer Res; 2010 Apr; 70(7):2891-900. PubMed ID: 20332228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated expression of MITF counteracts B-RAF-stimulated melanocyte and melanoma cell proliferation.
    Wellbrock C; Marais R
    J Cell Biol; 2005 Aug; 170(5):703-8. PubMed ID: 16129781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular pathways: adaptive kinome reprogramming in response to targeted inhibition of the BRAF-MEK-ERK pathway in cancer.
    Johnson GL; Stuhlmiller TJ; Angus SP; Zawistowski JS; Graves LM
    Clin Cancer Res; 2014 May; 20(10):2516-22. PubMed ID: 24664307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SPRY2 is an inhibitor of the ras/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild-type BRAF but not with the V599E mutant.
    Tsavachidou D; Coleman ML; Athanasiadis G; Li S; Licht JD; Olson MF; Weber BL
    Cancer Res; 2004 Aug; 64(16):5556-9. PubMed ID: 15313890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apoptosis of human melanoma cells induced by inhibition of B-RAFV600E involves preferential splicing of bimS.
    Jiang CC; Lai F; Tay KH; Croft A; Rizos H; Becker TM; Yang F; Liu H; Thorne RF; Hersey P; Zhang XD
    Cell Death Dis; 2010 Sep; 1(9):e69. PubMed ID: 21364673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.